Skip to main content

Table 2 Comparisons of the risk allele frequencies of 19 systemic lupus erythematosus autosomal loci in patients and controls stratified by sex and between men and women with SLE a

From: Lack of replication of higher genetic risk load in men than in women with systemic lupus erythematosus

   Men b Women b SLE men/SLE women
SNP c Gene locus SLE Control OR (95% CI) P-value SLE Control OR (95% CI) P-value OR (95% CI) d P-value
rs2476601 PTPN22 0.114 0.070 1.70 (1.09 to 2.64) 0.017 0.097 0.076 1.31 (1.08 to 1.60) 7.2 × 10−3 1.19 (0.80 to 1.77) 0.4
rs1801274 FCGR2A 0.493 0.474 1.08 (0.82 to 1.41) 0.6 0.511 0.474 1.15 (1.03 to 1.29) 0.011 0.93 (0.72 to 1.20) 0.6
rs2205960 TNFSF4 0.257 0.209 1.31 (0.96 to 1.79) 0.09 0.264 0.220 1.27 (1.12 to 1.45) 3.1 × 10−4 0.97 (0.72 to 1.29) 0.8
rs7574865 STAT4 0.306 0.209 1.67 (1.24 to 2.25) 7.1 × 10−4 0.325 0.243 1.49 (1.32 to 1.69) 2.8 × 10−10 0.92 (0.70 to 1.20) 0.5
rs6445975 PXK 0.311 0.241 1.42 (1.06 to 1.91) 0.018 0.264 0.226 1.23 (1.08 to 1.40) 2.2 × 10−3 1.26 (0.96 to 1.66) 0.09
rs17266594 BANK1 e 0.730 0.715 1.07 (0.80 to 1.45) 0.6 0.751 0.708 1.24 (1.09 to 1.41) 7.5 × 10−4 0.89 (0.67 to 1.19) 0.4
rs3131379 MSH5 (HLA) 0.132 0.071 1.98 (1.30 to 3.02) 1.2 × 10−3 0.146 0.072 2.20 (1.82 to 2.66) 9.6 × 10−17 0.89 (0.62 to 1.29) 0.5
rs729302 IRF5 0.711 0.689 1.11 (0.83 to 1.49) 0.5 0.748 0.691 1.33 (1.17 to 1.50) 1.0 × 10−5 0.83 (0.63 to 1.10) 0.2
rs10488631 IRF5 e 0.184 0.111 1.81 (1.26 to 2.61) 1.2 × 10−3 0.183 0.097 2.09 (1.76 to 2.48) 1.0 × 10−17 1.01 (0.73 to 1.40) 0.96
rs10954213 IRF5 0.639 0.638 1.01 (0.76 to 1.33) 0.97 0.685 0.643 1.21 (1.07 to 1.36) 1.9 × 10−3 0.82 (0.63 to 1.06) 0.13
rs13277113 C8orf13-BLK 0.274 0.250 1.13 (0.84 to 1.53) 0.4 0.311 0.245 1.39 (1.23 to 1.58) 2.8 × 10−7 0.84 (0.63 to 1.11) 0.2
rs4963128 KIAA1542 0.715 0.645 1.38 (1.03 to 1.85) 0.03 0.696 0.662 1.17 (1.04 to 1.32) 0.010 1.10 (0.83 to 1.45) 0.5
rs1143679 ITGAM 0.299 0.169 2.10 (1.54 to 2.85) 1.6 × 10−6 0.230 0.153 1.65 (1.42 to 1.90) 1.2 × 10−11 1.43 (1.08 to 1.88) 0.011
rs2304256 TYK2 0.735 0.723 1.06 (0.79 to 1.44) 0.7 0.770 0.727 1.26 (1.11 to 1.43) 4.8 × 10−4 0.83 (0.62 to 1.11) 0.2
rs5754217 UBE2L3 0.244 0.209 1.22 (0.89 to 1.67) 0.2 0.254 0.218 1.22 (1.07 to 1.39) 2.8 × 10−3 0.95 (0.71 to 1.27) 0.7
rs2230926 TNFAIP3 0.070 0.039 1.87 (1.07 to 3.27) 0.026 0.074 0.041 1.87 (1.45 to 2.40) 7.0 × 10−7 0.95 (0.58 to 1.55) 0.8
rs573775 ATG5 0.256 0.263 0.96 (0.71 to 1.30) 0.8 0.301 0.269 1.17 (1.04 to 1.33) 0.012 0.80 (0.60 to 1.06) 0.12
rs2187668 HLA-DQA1 0.184 0.107 1.87 (1.30 to 2.69) 6.0 × 10−4 0.201 0.105 2.15 (1.82 to 2.52) 7.4 × 10−21 0.89 (0.65 to 1.23) 0.5
rs10798269 1q25.1 0.733 0.656 1.20 (0.89 to 1.62) 0.2 0.729 0.680 1.26 (1.12 to 1.43) 1.7 × 10−4 1.02 (0.77 to 1.36) 0.9
  1. aSLE, Systemic lupus erythematosus; SNP, Single-nucleotide polymorphism. bSLE men = 136; control men = 540; SLE women = 1,321; Control women = 1,188. cThe 13 first loci are the same as those studied by Hughes et al. [9]. dOR > 1.0 indicates higher frequency of the risk allele in men than in women. e r2 = 0.94 with rs10516487 used for BANK1 and r2 = 0.94 for rs2070197 used for IRF5 [9].
Back to article page

Arthritis Research & Therapy

ISSN: 1478-6362

Contact us